Damora Therapeutics (DMRA) Non Operating Income (2019 - 2026)
Damora Therapeutics posted quarterly Non Operating Income of $3.1 million for Q1 2026, up 4414.71% year-on-year from $68000.0 in Q1 2025, and up 205.78% on a QoQ basis from $1.0 million in Q4 2025.
Damora Therapeutics (DMRA) has 8 years of Non Operating Income data on file, last reported at $3.1 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 4414.71% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $4.1 million (up 513.36% YoY), and the FY2025 full-year result was $1.1 million, up 25.64% from the prior year.
- Non Operating Income for Q1 2026 stood at $3.1 million, up from $1.0 million in the prior quarter.
- Across five years, Non Operating Income topped out at $3.1 million in Q1 2026 and bottomed at -$544000.0 in Q4 2022.
- The 5-year median for Non Operating Income is $234000.0 (2022), against an average of $362000.0.
- The widest annual swing landed in 2022, when Non Operating Income plunged 1022.03%; it then jumped 49700.0% in 2023.
- A 5-year view of Non Operating Income shows it stood at -$544000.0 in 2022, then jumped by 136.03% to $196000.0 in 2023, then surged by 80.1% to $353000.0 in 2024, then soared by 184.42% to $1.0 million in 2025, then jumped by 205.78% to $3.1 million in 2026.
- The last three Non Operating Income figures came in at $3.1 million (Q1 2026), $1.0 million (Q4 2025), and $23000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | 3.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.07 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 23,000.00 |
| Jun 30, 2025 | -12,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Dec 31, 2024 | 353,000.00 |
| Sep 30, 2024 | -36,000.00 |
| Jun 30, 2024 | 281,000.00 |
| Mar 31, 2024 | 264,000.00 |
| Dec 31, 2023 | 196,000.00 |
| Sep 30, 2023 | 447,000.00 |
| Jun 30, 2023 | 415,000.00 |
| Mar 31, 2023 | 498,000.00 |
| Dec 31, 2022 | -544,000.00 |
| Sep 30, 2022 | -108,000.00 |
| Jun 30, 2022 | 234,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | 59,000.00 |
| Sep 30, 2021 | 243,000.00 |
| Jun 30, 2021 | -34,000.00 |
| Mar 31, 2021 | 207,000.00 |
| Dec 31, 2020 | -275,000.00 |
| Sep 30, 2020 | -1.49 Mn |
| Jun 30, 2020 | 403,000.00 |
| Mar 31, 2020 | 156,000.00 |
| Dec 31, 2019 | 431,000.00 |
| Sep 30, 2019 | 721,000.00 |